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CONSOLIDATION OF P2Y12 TESTING WHILE MAINTAINING QUALITY AND 
TURNAROUND TIME 
Geetha Jagannathan, MBBS; Jerald Gong, MD 
Department of Anatomy, Pathology and Cell Biology, Thomas Jefferson University, Philadelphia 
 
Approved by the FDA in 1997, clopidogrel (Plavix) is 
a commonly used prophylactic antiplatelet 
medication.  
Mechanism of action: Clopidogrel irreversibly binds 
to adenosine diphosphate (ADP) platelet receptor 
P2Y12 and prevents activation of glycoprotein 
IIb/IIIa, preventing platelet aggregation.  
 
VerifyNow PRU® is a lab blood test that measures 
the level of P2Y12 receptor blockade in patients 
treated with clopidogrel and newer drugs, prasugrel 
and ticagrelor.  
 
When are Patients on P2Y12 inhibitors tested?  
1. Preoperatively to assess the risk of bleeding and 
to time the surgery. 2. To determine resistance to 
the drug and appropriate dosing.  
 
Problem? 
● Currently, the assay is performed at 2 locations: 
Thomas Jefferson University Hospital(TJUH) and 
Jefferson Hospital for Neuroscience(JHN).  
● 10X more tests are ordered at JHN than at TJUH. 
●  Maintaining and running the assay for a small 
volume of samples at TJUH is expensive without 
an established benefit in patient safety 
or quality of care. 
 
● This project was approved by the Cardiology and 
Thrombosis Subcommittee and will be 
implemented in the near future following EPIC 
go-live. 
 
 • In 2016, the clinical laboratory at TJUH performed 
VerifyNow PRU® P2Y12 assay on 31 samples, and 
JHN on 465 patient samples. 
 
• The cost for testing the 31 samples at TJUH: 
 
 
 
 
 
 
 
 
 
• The cost of testing the 31 samples at JHN upon  
test location consolidated is estimated as: 
 
 
 
 
 
 
 
Reagent cost per test sample: $60  
Reagent cost of control for each test: $200 
Total cost per test sample: $60 + $200 = $ 260 
Reagent cost for weekly instrument calibration 
with controls : $200 
Total expenditure in 2016:  
($260 x 31) + ($200 x 52) = $18,460 
 
 
Total reagent cost of 31 samples: $60 x 31= $1,860 
No cost for calibration since it is already being 
performed on  the instrument at JHN 
Potential total saving: $18,460- $1,860= $16,600 
 
Potential challenges: 
• VerifyNow PRU® P2Y12 is run within 4 hours of 
collection of the blood sample which is  
delivered manually to the lab.  
• Consolidation will require a courier service for 
transport of samples from TJUH to JHN. 
 
• By consolidating, VerifyNow PRU® P2Y12  assay 
will be managed by 1 team of technicians at 1 
location, ensuring better standardization and 
quality.    
• Data will be collected for a period of 1 year 
following implementation. 
 
 
 
 
 
 
 
 
 
 
• If successful, this measure can be applied to 
similar tests run at different locations within 
the hospital. 
 
● To consolidate the test performed at 2 different 
locations to 1, thereby improving  cost 
effectiveness while maintaining  quality and 
result turnaround time.  
 
Measures to be tested 
Outcome Result turnaround time from blood 
draw, any delay in reporting 
Process  Time taken to transport samples 
Balancing 
metrics 
Ensure transport/courier cost does not 
outweigh the cost effectiveness of 
measure 
25 
6 
Inpatient vs outpatient  
Inpatient
Outpatient
16 
3 
6 
6 
Departments ordering assay 
Neurosurgery
Cardiothoracic
Cardiology
Other
Data collected at TJUH lab for 2016 
Median turnaround time 50mins 
Delay in reporting 2 samples (technical 
errors), by 11 and 16 hrs  
No. of stat orders None 
